Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

15.58EUR
18 Apr 2019
Change (% chg)

€-0.34 (-2.14%)
Prev Close
€15.92
Open
€15.80
Day's High
€15.83
Day's Low
€15.41
Volume
109,187
Avg. Vol
458,681
52-wk High
€44.20
52-wk Low
€7.59

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.89
Market Cap(Mil.): €566.60
Shares Outstanding(Mil.): 36.16
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 62.06 62.40
EPS (TTM): -5.78 -- --
ROI: -122.98 12.17 11.78
ROE: -132.22 13.11 12.61

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

06 Mar 2019

BRIEF-DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019

* ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE

14 Feb 2019

Earnings vs. Estimates